• Logo
  • SBMUJournals

Serum Resistin levels in bladder cancer

Mahmoud Mohammadi, Jalil Hosseini, Morteza Fallah Karkan, Mehdi Hedayati
30

Views

PDF

Abstract

Background: Adipokines play a role in pathogenesis and progression of certain cancers. Resistin is an adipokine with diverse findings in disease development and progression. The present study aimed to determine Resistin serum levels in bladder cancer cases in order to identify novel tumor markers.

Methods: This research was based on a case-control study, including 45 patients with bladder cancer and 45 healthy controls. Resistin levels were measured by ELISA in both groups. Height and weight were measured and body mass index (kg/m2) was calculated.

Results: Resistin levels were significantly different between bladder cancer and the control group (p<0.0001) but Resistin levels in different stages were not significantly different. Also there was no correlation among sex, age, body mass index and the serum Resistin levels.

Conclusions: These results suggest that changes in serum Resistin levels play an important role in the diagnosis and could act as a biomarkers for bladder cancer.

 


References

Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. 2018. 68(1): p. 7-30.

Rübben, H., et al., Natural history and treatment of low and high risk superficial bladder tumors. The Journal of urology, 1988. 139(2): p. 283-285.

Millan-Rodriguez, F., et al., Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. The Journal of urology, 2000. 164(3): p. 680-684.

Pelucchi, C., et al., Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol, 2006. 3(6): p. 327-40.

Smith, M., et al., Esophageal cancer and body mass index: results from a prospective study of 220,000 men in China and a meta-analysis of published studies. Int J Cancer, 2008. 122(7): p. 1604-10.

Aune, D., et al., Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol, 2012. 23(4): p. 843-52.

Harriss, D.J., et al., Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. Colorectal Dis, 2009. 11(6): p. 547-63.

Secord, A.A., et al., Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol, 2016. 140(1): p. 184-90.

Chan, D.S., et al., Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol, 2014. 25(10): p. 1901-14.

Qin, Q., et al., Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev, 2013. 14(5): p. 3117-21.

Conde, J., et al., Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors, 2011. 37(6): p. 413-20.

Sahin-Efe, A., F. Katsikeris, and C.S. Mantzoros, Advances in adipokines. Metabolism, 2012. 61(12): p. 1659-65.

Jung, U.J. and M.S. Choi, Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci, 2014. 15(4): p. 6184-223.

Dalamaga, M., Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med, 2014. 8(1): p. 107-18.

Wang, H., et al., Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab, 2002. 87(6): p. 2520-4.

Smalley, D.M., et al., Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res, 2008. 7(5): p. 2088-96.

Assiri, A.M.A., H.F.M. Kamel, and M.F.R. Hassanien, Resistin, Visfatin, Adiponectin, and Leptin: Risk of Breast Cancer in Pre- and Postmenopausal Saudi Females and Their Possible Diagnostic and Predictive Implications as Novel Biomarkers. Disease Markers, 2015. 2015: p. 9.

Gorgian Mohammadi, M., et al., Adipocyte Derived Hormones Gene Expression, Resistin and Visfatin, in AGS Gastric Cancer Cell Line. Iran J Cancer Prev, 2013. 6(3): p. 165-9.

Karapanagiotou, E.M., et al., The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung cancer, 2008. 61(3): p. 391-397.

Kaser, S., et al., Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun, 2003. 309(2): p. 286-90.

Kolosova, I.A., et al., Resistin-like molecule alpha stimulates proliferation of mesenchymal stem cells while maintaining their multipotency. Stem Cells Dev, 2013. 22(2): p. 239-47.

Kim, H.J., et al., Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU international, 2011. 108(2b).

Mohammadi, M., et al., RESISTIN EFFECT ON TELOMERASE GENE EXPRESSION IN GASTRIC CANCER CELL LINE AGS. Acta Endocrinologica (1841-0987), 2016. 12(2).

Mohammadi, M., et al., Synergistic Effects of Resistin and Visfatin as Adipocyte Derived Hormones on Telomerase Gene Expression in AGS Gastric Cancer Cell Line. Acta Med Iran, 2017. 55(10): p. 621-627.


Refbacks

  • There are currently no refbacks.